A Study Of BRL49653C For The Treatment Of Type 2 Diabetes

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 3

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: rosiglitazone

Study type: Interventional

Funder types: Industry

Identifiers

NCT00523913

AVD105720

Details and patient eligibility

About

This study is designed to evaluate the safety of BRL49653C administrated for 52 weeks

Enrollment: 70 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with type 2 diabetes mellitus managed by diet therapy or one antidiabetic agent (sulfonylurea or alpha glucosidase inhibitor) will be candidates for this study. These candidates will be checked up on their clinical laboratory data, and must have adequate blood, liver and kidney function.

Exclusion criteria

• Patient with serious cardiovascular disease or serious hepatic disease will not be eligible.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)